China Life Sets Out Board Line-Up and Committee Roles

An update from China Life Insurance Co ( (HK:2628) ) is now available.

China Life Insurance Company Limited has announced the current composition of its board of directors, led by Chairman and Executive Director Cai Xiliang, and including executive, non-executive, independent non-executive, and an employee representative director. The company also detailed the membership and chairmanship of its five key board committees—Audit, Nomination and Remuneration, Risk Management and Consumer Rights Protection, Strategy and Assets and Liabilities Management, and Connected Transactions Control—clarifying governance responsibilities among directors and signaling its emphasis on structured oversight and risk management.

The clarified allocation of committee roles underscores China Life’s efforts to strengthen corporate governance and transparency for shareholders and regulators. By specifying which independent directors chair critical committees such as audit, nomination, and connected transactions control, the insurer highlights its alignment with best practices in board independence and oversight within China’s financial services sector.

The most recent analyst rating on (HK:2628) stock is a Buy with a HK$40.00 price target. To see the full list of analyst forecasts on China Life Insurance Co stock, see the HK:2628 Stock Forecast page.

More about China Life Insurance Co

China Life Insurance Company Limited is a major life insurer in mainland China, operating as a joint stock company with limited liability and listed under stock code 2628. The company focuses on life insurance and related financial protection products, serving a broad base of policyholders and stakeholders in the Chinese insurance market.

Average Trading Volume: 65,097,711

Technical Sentiment Signal: Buy

Current Market Cap: HK$1238.7B

For a thorough assessment of 2628 stock, go to TipRanks’ Stock Analysis page.